|
CPhI Middle East & Africa to take place at Abu Dhabi from September 16-18
|
|
Our Bureau, Mumbai
May 20 , 2019
|
|
|
CPhI Middle East & Africa (CPhI MEA) will take place at the ADNEC
Centre, Abu Dhabi, United Arab Emirates (UAE), from September 16-18
,2019, attracting leaders and key decision makers to the heart of this
new pharma hub. The event will co-locate ICSE, P-MEC, Innopack and FDF,
providing the opportunity to meet with regional drug manufacturers,
suppliers of pharma ingredients, distributors, finished dose
manufacturers, and companies involved in pharma machinery, packaging and
contract services.
According to CPhI MEA expert Madhukar Tanna,
Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based
branded generic manufacturer, favourable conditions in the UAE are
resulting in a boom of pharmaceutical manufacturing throughout the
region. Government incentive schemes to increase domestic production,
coupled with a brand friendly environment and rising healthcare needs is
fuelling surging demand – with many new companies and plants launching
in the last two years alone.
Currently, the UAE imports 90 per
cent of medicines, with generics accounting for up to 60 per cent of
these imports. However, it has been well-publicised that the UAE has
identified pharmaceutical manufacturing as a key growth area, with the
number of domestic pharmaceutical companies expected to increase
significantly.
Experts believe ahead of the second CPhI MEA –
where nearly 4,900 professionals and 294+ exhibiting companies will be
in attendance – the opportunities in the region are rapidly opening-up
and many international firms are now looking to partner with local
manufacturers to bring products to market. As an example of the
increased internationalisation across the region, representatives from
more than 100 countries are expected in only the event’s second edition.
This year’s event will include finished dose drug companies,
ingredients suppliers as well as contract manufacturers and machinery
specialists – who are responding to the growth potential of the region.
Interestingly,
many manufacturers in the region are operating a new type of regional
partnering model. For example, the drive towards locally produced final
products in the UAE is supported by development work and process
chemistry conducted outside the UAE, and bioequivalence studies from
countries such as Jordan. Then once the product has completed
development and is ready for commercial sale, manufacturing is
transferred to a local manufacturing site in Dubai.
The
conditions have come together synergistically in the last few years,
with investors helping build improved plants and launch entirely new
companies. It is anticipated that as many as 20 more facilities could be
added in the next few years, with the UAE emerging as a new final
product manufacturing hub.
“At CPhI MEA we have seen a notable
increase in new finished product manufacturers across the region looking
to work with international partners for development and API, as well as
sourcing regional distributors. The conditions are really favourable,
and we continue to see an expanding base of manufacturing, particularly
in the UAE, Jordan and Saudi Arabia.” added Cara Turner, Brand Director
at Informa.
The pharma market in MENA was worth US$ 31.8 billion
in 2018 and is forecast to grow with a compound annual growth rate of
6.9% reaching US$ 41.5 billion by 2022. Saudi Arabia remains the biggest
overall market.
Another area highlighted for potential future
growth are in inhalers and biosimilars – in particular we should expect
companies to begin investing in sterile capabilities across the region –
where there is a particularly noticeable gap in the domestic
manufacturing production capabilities.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|